Investor Dashboard

News Releases

Date Title and Summary Additional Formats
Toggle Summary NuCana to Present at the Morgan Stanley 17th Annual Global Healthcare Conference
EDINBURGH, United Kingdom , Aug. 29, 2019 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced today that Hugh Griffith , Chief Executive Officer, and Don Munoz , Chief Financial Officer, will present and host one-on-one meetings at the Morgan Stanley 17th Annual Global Healthcare Conference in
View HTML
Toggle Summary NuCana to Participate in Citi’s 14th Annual Biotech Conference
EDINBURGH, United Kingdom , Aug. 27, 2019 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced today that Hugh Griffith , Chief Executive Officer, and Don Munoz , Chief Financial Officer, will host one-on-one meetings at Citi’s 14th Annual Biotech Conference in Boston on September 5 th , 2019.
View HTML
Toggle Summary NuCana Reports Second Quarter 2019 Financial Results and Provides Business Update
Numerous Clinical Data Announcements and Study Initiations Expected in 2019 Current Cash Balance Expected to Fund the Company Into 2021 EDINBURGH, United Kingdom , Aug. 21, 2019 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced financial results for the second quarter ended June 30, 2019 and
View HTML
Toggle Summary Enrollment in the Independent Investigator-Sponsored Phase III Metastatic Pancreatic Study ACELARATE Has Been Suspended Following a Prespecified Futility Analysis
Imbalances in Prognostic Factors May Have Impacted Analysis Longer-term Follow-up by Study Sponsor is Ongoing to Determine Path Forward Encouraging Survival Trends Observed in Patient Sub-Groups Receiving Acelarin Monotherapy Informs Future Development in Pancreatic Cancer LIVERPOOL, United Kingdom
View HTML
Toggle Summary NuCana Announces First Patients Dosed in Phase I Study of NUC-7738
NUC-7738 is NuCana’s Third ProTide to Enter the Clinic Study Will Enroll Up To 61 Patients with Advanced Solid Tumors EDINBURGH, United Kingdom , July 17, 2019 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA), a clinical-stage biopharmaceutical company focused on significantly improving treatment
View HTML
Toggle Summary NuCana Receives Orphan Drug Designation from the U.S. Food and Drug Administration for Acelarin® for the Treatment of Biliary Tract Cancer
NuCana Remains on Track to Open Global Phase III Study in 2019 EDINBURGH, United Kingdom , June 12, 2019 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) today announced that the U.S. Food and Drug Administration ( FDA ) has granted orphan drug designation for the Company’s investigational drug,
View HTML
Toggle Summary NuCana to Present at the Jefferies 2019 Healthcare Conference
EDINBURGH, United Kingdom , May 30, 2019 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced today that Hugh Griffith , Chief Executive Officer, and Don Munoz , Chief Financial Officer, will present and host one-on-one meetings at the Jefferies 2019 Healthcare Conference in New York, NY .
View HTML
Toggle Summary NuCana Reports First Quarter 2019 Financial Results and Provides Business Update
Numerous Clinical Data Announcements and Study Initiations Expected in 2019 Current Cash Balance Expected to Fund the Company Into 2021 EDINBURGH, United Kingdom , May 14, 2019 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced financial results for the first quarter ended March 31, 2019 and
View HTML
Toggle Summary NuCana to Participate in the William Blair 3rd Late-Stage Therapeutics Conference
EDINBURGH, United Kingdom , April 02, 2019 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA), a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer, announced today that Don Munoz , Chief Financial Officer, will host one-on-one
View HTML
Toggle Summary NuCana Reports Fourth Quarter and Year-End 2018 Financial Results and Provides Business Update
Numerous Clinical Data Announcements and Study Initiations Expected in 2019 Current Cash Balance Expected to Fund the Company Into 2021 EDINBURGH, United Kingdom , March 07, 2019 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced financial results for the fourth quarter and year ended December
View HTML